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Abstract
Background: In the Netherlands, from 2007 to 2009, 3,522 Q-fever cases were notified from three outbreaks. These
are the largest documented outbreaks in the world. Previous studies suggest that symptoms can persist for a long
period of time, resulting in a reduced quality of life (QoL). The aim of this study was to qualify and quantify the
health status of Q-fever patients after long-term follow-up.
Methods: 870 Q-fever patients of the 2007 and 2008 outbreaks were mailed a questionnaire 12 to 26 months after
the onset of illness. We assessed demographic data and measured health status with the Nijmegen Clinical
Screening Instrument (NCSI). The NCSI consists of three main domains of functional impairment, symptoms and
QoL that are divided into eight sub-domains. The NCSI scores of Q-fever patients older than 50 years (N = 277)
were compared with patients younger than 50 years (N = 238) and with norm data from healthy individuals (N =
65) and patients with chronic obstructive pulmonary disease (N = 128).
Results: The response rate was 65.7%. After applying exclusion criteria 515 Q-fever patients were included in this
study. The long-term health status of two thirds of Q-fever patients (both younger and older than 50 years) was
severely affected for at least one sub-domain. Patients scores were most severely affected on the sub-domains
general QoL (44.9%) and fatigue (43.5%). Hospitalisation in the acute phase was significantly related to long-term
behavioural impairment (OR 2.8, CI 1.5-5.1), poor health related QoL (OR 2.3,CI 1.5-4.0) and subjective symptoms
(OR 1.9, CI 1.1-3.6). Lung or heart disease, depression and arthritis significantly affected the long-term health status
of Q-fever patients.
Conclusions: Q-fever patients presented 12 to 26 months after the onset of illness severe -clinically relevant-
subjective symptoms, functional impairment and impaired QoL. All measured sub-domains of the health status
were impaired. Hospitalisation and co-morbidity were predictors for worse scores. Our data emphasise that more
attention is needed not only to prevent exposure to Q-fever but also for the prevention and treatment of the
long-term consequences of this zoönosis.
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Background
Q-fever is a worldwide zoönotic disease caused by Cox-
iella burnetii (C. burnetii), an obligate intracellular bac-
terium. Until 2007 Q-fever was uncommon in the
Netherlands, with 5-20 notified cases annually [1]. From
2007-2009, 3,522 cases were notified in three large out-
breaks [2], with dairy goats implicated as the source
[1,2]. The majority of Q-fever patients (80%) reside in
the southern province of Noord-Brabant [1-3]. Between
2007 and early 2010 some hard-hit communities suf-
fered a cumulative incidence of 2,650 notified Q-fever
cases per 100,000 inhabitants (one in 38 people).
In general 60% of infected Q-fever patients are asymp-
tomatic, while 20% develop mild symptoms [4]. The
remaining 20% of Q-fever patients present with more
severe symptoms ranging from high fever, severe head-
ache, night sweating, nausea and diarrhoea, to pneumo-
nia, hepatitis, pericarditis, myocarditis and neurological
* Correspondence: g.morroy@ggdhvb.nl
1Department of Infectious Disease Control, Municipal Health Service Hart
voor Brabant, ‘s-Hertogenbosch, the Netherlands
Full list of author information is available at the end of the article
Morroy et al. BMC Infectious Diseases 2011, 11:97
http://www.biomedcentral.com/1471-2334/11/97
© 2011 Morroy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.symptoms [5]. Chronic Q-fever may develop in 1.5-5%
of acute cases, due to reactivation of C. burnetii [4,6,7].
A feared complication is endocarditis, which may take
10-15 years to develop. In particular pregnant women
and patients with heart valve disorders, vascular pros-
thesis and impaired immunity have a higher risk to
develop chronic infection [4,6,7]. Protracted fatigue up
to 10 years after infection [8,9] is another late sequel. A
Post-Infection Fatigue Syndrome (PIFS) [9] may also
occur after other infections such as Lyme disease [10].
In 10-15% of Q-fever patients fatigue can last up to 5-
10 years [11] and is referred to as Post Q-fever fatigue
Syndrome (PQFS). Other authors [8,9] state higher per-
centages of fatigue. PQFS presents with symptoms
resembling those of Chronic Fatigue Syndrome (CFS).
During the Dutch Q-fever outbreaks patients and gen-
eral practitioners (GPs) repeatedly reported persisting
symptoms to the public health authorities and in parti-
cular about fatigue. These signals could not be substan-
tiated, as we lacked specific information on the health
status at individual and at Q-fever patient population
level. Furthermore, we were uncertain whether data
from other small national [12] and international studies,
would also apply to our large Dutch Q-fever cohorts. In
o r d e rt oa s s e s st h el o n g - t e r mh e a l t hs t a t u so fD u t c hQ -
fever patients we started this study.
Long-term health status impairment may have a large
impact on patients, their families and the societies that
they are part of. In this study, the primary aim was to
provide a detailed assessment of the health status of Q-
fever patients 12 to 26 months after the onset of illness.
This information will assist clinicians and patients to
better understand the natural course, consequences of
the disease and predictors for an affected health status.
Methods
Q-Quest I study
This cohort study is part of the collaborative Q-Quest I
study, which aims to measure the impact of the Q-fever
outbreaks in terms of population health and societal
implications. The study started in May 2008 and
includes studies on diagnostics, treatment, clinical symp-
toms, costs and the long-term health status.
Study design and population
Eligible for inclusion in this study were Q-fever patients
notified in 2007 and 2008 to the Municipal Health Ser-
vice “Hart voor Brabant” and “Brabant Zuid-Oost” with
a first day of illness in 2007 or 2008. All patients fitted
the Dutch notification criteria; a laboratory confirmation
of Q-fever and clinical presentation of fever, pneumonia
or hepatitis. Patients were diagnosed by 4 different
laboratories. At the beginning of the outbreak in 2007
the laboratory test most frequently used was the CFT
(complement fixation test). A sero-conversion or a four-
fold increase in titre, between two subsequent tests with
a minimum time interval of two to four weeks, was con-
sidered positive. Later during the outbreak one labora-
tory used the IFA (Immuno Fluorescence Assay). This
latter test distinguished between phase I en II IgM and
IgG [13].
Exclusion criteria were: an unknown onset of Q-fever
infection, a questionnaire completed by another person
or an incomplete questionnaire. Participants younger
than 18 years of age, were excluded because the ques-
tionnaire instruments were developed for adults.
Questionnaires
All patients that agreed to participate in the Q-Quest I
study, received a questionnaire that comprised two
parts: the cost and symptoms questionnaire which col-
lected data on demographics, self reported symptoms,
co morbidity, hospitalisation, healthcare consumption,
education and employment and the Nijmegen Clinical
Screening Instrument (NCSI) [14] to measure health
status.
The NCSI is based on an empirical definition of health
status [15], covering physiological functioning, symp-
toms, functional impairment, and quality of life (Qol) as
main domains. In this study we only measured the main
domains symptoms, functional impairment and QoL.
These main domains are subdivided into 8 sub-domains:
subjective symptoms; dyspnoea emotions; fatigue; beha-
vioural impairment; subjective impairment; general
Quality of Life (General QoL); Health Related Quality of
Life (HRQoL); and satisfaction with relations [14]. Con-
sult table 1 for definitions and instruments [15-20] of
the sub-domains of health status measured by the NCSI.
The NCSI provides normative data indicating normal
functioning, mild - or severe problems for each sub-
domain. The NCSI contains 8 sub-domains, each
expressed as a single score on its own scale. Thus eight
different scales were used. The score range indicating
severe problems was based on patients with COPD
attending a multidisciplinary inpatient pulmonary reha-
bilitation program (n = 128). The key requirement for
inclusion was severe problems in multiple areas of the
health status. This decision was based on a three-day
intake procedure, in which elaborate assessment, physio-
logical tests and clinical interviews with seven medical
disciplines were undertaken. The score range indicating
normal functioning was based on a group of healthy
subjects (n = 65). Scores below the 80th percentile of
healthy controls indicate the score range of normal
functioning. Scores above the 20th percentile of the pul-
monary rehabilitation group indicate the score range of
severe problems. Higher NCSI scores indicate more pro-
blems. For more details see Peters et al [14].
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In February 2009, 870 patients received a Q-Quest study
information folder and a participation request form by
post. Patients could state their willingness to take part
in any of the Q-Quest I studies by signing the consent-
form. All patients from the 2007 cohort received a Q-
Quest I questionnaire (12-26 months after onset of Q-
fever illness) together with the consent form in February
2009. Patients from the 2008 cohort, who had stated
their willingness to participate, were mailed the ques-
tionnaire exactly one year after the month of onset of
illness. If questionnaires were not returned within three
weeks, patients from both cohorts received two remin-
ders three weeks apart. See figure 1 for detailed
information.
The study design and protocol were approved by the
local Medical Ethics Review Committee of the Jeroen
Bosch Hospital.
Data analysis
In this study we compared the Q-fever patients NCSI
scores with those of the norm groups: healthy indivi-
duals (n = 65) and the special group of severe COPD
patients (n = 128).
Questionnaires were double scanned in November
2009. SPSS 15.0 for windows was used for statistical
analysis. P-values were based on two tailed tests with P
< 0.05 defined as significant. Chi-square test was used
to compare proportions. Logistic regression and the
general linear model were used to model outcomes (8
sub-domains of NCSI) for the three groups (healthy
COPD-norm group and Q-fever patients), while control-
ling for the potential confounders: age, gender, smoking
and education-level. During logistic regression we
regrouped the outcomes normal, mild and severe for the
8 sub-domains into normal and abnormal (combining
mild and severe). Notification data of the Municipal
Health Service enabled us to compare Q-fever respon-
dents and non responders for year of onset of illness,
age, gender and hospitalisation at the acute stage of the
infection. As the control groups providing the normative
data for the NCSI were older than 50 years, Q-fever
patients younger than 50 years of age were analyzed
separately from patients older than 50 years.
For comparison of participating Q-fever patients
younger or older than 50 years of age, we also looked at
co-morbidity and hospitalisation. These data were una-
vailable for healthy individuals and COPD patients.
Results
Patient participation
Of the 898 patients notified in 2007-2008, 28 were
excluded due to incomplete data or unknown month
of onset of illness (figure 1). Of the 5 patients that
died, we lacked information on the cause of death. In
total 572 questionnaires were received (65.7%). Fewer
men than women returned the questionnaire (respon-
ders vs. non-responders women 223/106, men 323/218
p = 0.017). The response rate was higher for patients
aged over 35 (P = 0.011). After excluding participants
younger than 18 years (n = 9), participants who did
not complete the questionnaire themselves (n = 22)
and incomplete questionnaires (n = 26), 515 question-
naires were left (see figure 1). The mean interval
between the first day of illness for Q-fever patients of
cohort 2007 and cohort 2008 and filling out the ques-
tionnaire was 19.6 months (SD 2.3) and 11.6 months
(SD 1.0), respectively.
Table 1 Definitions and instruments of the health status sub-domains measured by the Nijmegen Clinical Screening
Instrument
Domain Sub-domain Definition Instruments
Symptoms Subjective
symptoms
The patient’s overall burden of pulmonary symptoms PARS-D Global Dyspnea Activity,
Global Dyspnea Burden (15)
Dyspnoea
emotions
The level of frustration and anxiety a person experiences when
dyspnoeic
DEQ Frustration, Anxiety (15)
Fatigue The level of experienced fatigue CIS Subjective fatigue (16)
Functional
impairment
Behavioural
impairment
The extent to which a person cannot perform specific and concrete
activities as a result of having the disease
SIP Home Management, Ambulation
(17)
Subjective
impairment
The experienced degree of impairment in general and in social
functioning
QoLRiQ General Activities (18)
Quality of Life General Quality of
Life
Mood and the satisfaction of a person with his/her life as a whole BDI Primary Care (19) Satisfaction With
Life Scale (20)
Health-related
Quality of Life
Satisfaction related to physiological functioning and the future Satisfaction Physiological Functioning,
Satisfaction Future (15)
Satisfaction
relations
Satisfaction with the (absent) relationships with spouse and others Satisfaction spouse, Satisfaction social
(15)
PARS-D: Physical Activity Rating Scale-Dyspnea; DEQ: Dyspnea Emotions Questionnaire; CIS: Checklist Individual Strength; SIP: Sickness Impact Profile; QoLRiQ: Quality of
Life for Respiratory Illness Questionnaire; BDI: Beck Depression Inventory
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Q-fever patients, the healthy and COPD norm group
were similar with respect to gender and level of educa-
tion. The characteristics of the study population are pre-
sented in table 2.
Health status
The long-term health status of Q-fever patients was
severely affected especially for the sub-domains General
QoL (44.9%) and fatigue (43.5%) (see figure 2). Almost
two fifths of the Q-fever patients (38.2%) older than 50
years, had severe problems on more than one sub-
domain (see figure 3). Of the Q-fever patients with
abnormal fatigue, 79.5% also reported abnormal scores
on subjective symptoms, 77.9% on behavioural impair-
ment, 65.0% on HRQoL, 60.7% on dyspnoea emotions
and 57.7% on General QoL.
Female Q-fever patients consistently reported abnor-
mal functioning (mild and severe on the sub-domains of
the NCSI) more frequently than males. This difference
Figure 1 Flowchart. Response rate of 898 Q-fever patients with onset of disease in 2007 and 2008
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of the women vs. 28.1% of the men, p = 0.012).
No significant differences were found for 7 sub-
domain scores between Q-fever patients older and
younger than 50 years. Although the frequency with
which dyspnoea was reported was similar for the age
groups (45.8% >50 years n = 277 and 42.9% < 50 years
n = 238) patients younger than 50 years suffered more
often from dyspnoea emotions (OR 2.0, CI 1.3-3.1 p =
0.001).
In comparison to the healthy norm score, Q-fever
patients showed significantly more abnormal health sta-
tus (mild and severe) in 7 of the 8 sub-domains (see
table 3). The worst scores were found for the sub-
domains fatigue, subjective symptoms and subjective
impairment. Q-fever patients had significantly lower
(healthier) scores in all 8 NCSI-sub-domains, compared
to the COPD-norm score.
The year of onset of illness, level of education and
smoking behaviour had no significant influence on sub-
domain mean scores. However, patients that were hospi-
talised (23.6% of patients older than 50 years) during the
onset of illness or with underlying heart or lung disease,
arthritis and depression scored significantly worse for
several sub-domains (see table 4). The outcomes for
patients younger than 50 years were similar.
Heart disease increased the risk for an abnormal out-
come for the sub-domains subjective symptoms,
Table 2 Characteristics of the study population
Characteristics Q-fever COPD- Healthy Total
Age <50 >50 yrs
N = 238 (%) N = 277 (%) N = 128 (%) N = 65 (%) N = 708
Gender
Male 140 (58.8) 166 (59.9) 86 (67.2) 47 (72.3) 439
Female 98 (41.2) 111 (40.1) 42 (32.8) 18 (27.7) 269
Age
Mean 40.4 60.3 62.5 63.5 56.7
SD 7.4 7.6 6.9 6.6
Current smoking
Yes 96 (40.3) 71 (26.6) 11 (8.9) 11 (16.9) 189
No 137 (57.6) 196 (73.4) 113 (91.1) 54 (83.1) 500
Education-level
Low 56 (23.5) 97 (35.5) 62 (50.4) 20 (30.8) 235
Average 120 (50.4) 126 (46.2) 38 (30.9) 26 (40.0) 310
High 60 (25.2) 50 (18.3) 23 (18.7) 19 (29.2) 152
Q-fever patients younger and older than 50 years, Norm groups Chronic Obstructive Pulmonary Disease- and healthy individuals. Q-fever patients >50 currently
smoke significantly more than COPD-controls. None of the other characteristics differ significantly (logistic regression).
Figure 2 The 8 sub-domain scores of Q-fever patients older (n = 277) and younger than 50 years of age (N = 238).
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pnoea emotions. Lung disease had a negative influence on
the outcome of the first three aforementioned domains.
Discussion
The present study is the largest and longest follow-up
study of Dutch Q-fever patients of the 2007 and 2008
outbreaks. Using a validated questionnaire, the Nijme-
gen Clinical Screening Instrument (NCSI), we provided
a detailed assessment of the long-term effects of Q-fever
on health status 12-26 months after onset of illness. The
most important finding of this study was that, in two
thirds of Q-fever patients of all ages, at least one sub-
domain was severely (clinically) affected up to 26
months after the initial illness. The sub-domains Gen-
eral QoL (44.9%) and fatigue (43.5%) were most fre-
quently severely affected.
Published data on health status, and its sub-domains,
in Q-fever patients are scarce. Hatchette reported [21]
that 52% of Q-fever patients were symptomatic and had
an impaired QoL 27 months after infection, with signifi-
cant lower scores on five of eight domains of the Medi-
cal Outcomes Study 36-Item Short-Form Health Survey
(SF-36), as compared to non-infected controls. Impaired
domains were: physical pain, physical function, emo-
tional role, physical role and social function.
Figure 3 Percentage of Q-fever patients with the number of severely affected domains of the health status.
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mal (mild and severe) fatigue. This is similar to other
publications that state 68.7% [9] five and 64.9% [8] pro-
tracted fatigue up to ten to years after infection. Unfor-
tunately we were unable to establish if Q fever patients
mainly suffered fatigue the first year and later recovered
as we only had contact with patients once. The fact that
we found no differences between patients of the 2007
and 2008 cohorts is suggestive of persisting complaints.
Some studies state that cytokine deregulation and
immuno-modulation from persistence of C. burnetii,
might be responsible [22] for prolonged fatigue, but
others contradict this [23].
Other studies find prolonged impairment of the health
status months after legionellosis and pneumonia. Dutch
pneumonia patients had significantly affected SF-36
scores 18 months after pneumonia on the subscales phy-
sical function and general health status [24]. Survivors of
a Legionnaires Disease-outbreak in the Netherlands
reported 17 months after infection severely impaired SF-
36-domains: physical role function, general health and
vitality [25]. Up to 75.0% of patients reported fatigue
[25]. Although all three infectious diseases seem to cause
long-term impairment; the impaired sub-domains differ.
The severity of initial illness in general negatively
influences the long-term QoL [26,27]. Similarly, the
Table 3 Comparison 8 NCSI sub-domains scores between Q-fever patients > 50 years and the healthy norm group
Domain and subdomain Q-fever n = 277 (%) Healthy control n = 65 (%) Q-fever vs. healthy(ref)
n = 277 (%) n = 65 (%) OR (CI) P value
Symptoms
Subjective symptoms
N 255 65
Normal 123 (48.2) 59 (90.8)
Abnormal 132 (51.8) 6 (9.2) 9.9 (4.0-24.5) 0.000
Dyspnoea emotions
N 172 65
Normal 103 (59.9) 55 (84.6)
Abnormal 69 (40.1) 10 (15.4) 3.1 (1.4-6.8) 0.006
Fatigue
N 207 65
Normal 85 (41.1) 57 (87.7)
Abnormal 122 (58.9) 8 (12.3) 9.2 (4.0-20.8) 0.000
Functional impairment
Behavioural impairment
N 277 65
Normal 126 (45.5) 49 (75.4)
Abnormal 151 (54.5) 16 (24.6) 3.8 (1.9-7.3) 0.000
Subjective impairment
N 249 65
Normal 173 (69.5) 60 (92.3)
Abnormal 76 (30.5) 5 (7.7) 5.0 (1.9-13.4) 0.001
Quality of life
General Quality of Life
N 234 65
Normal 129 (55.1) 51 (78.5)
Abnormal 105 (44.9) 14 (21.5) 2.4 (1.2-4.7) 0.011
Health related Quality of Life
N 271 65
Normal 151 (55.7) 55 (84.6)
Abnormal 120 (44.3) 10 (15.4) 3.7 (1.8-7.7) 0.001
Satisfaction relations
N 252 65
Normal 166 (65.9) 37 (56.9)
Abnormal 86 (34.1) 28 (43.1) 0.5 (0.3-0.9) 0.040
Abnormal is a combination of mild and severe scores. Used method chi square.
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term symptoms [28]. Our study shows that hospitalised
patients more often scored abnormal on the sub-
domains HRQoL, behavioural impairment and subjective
symptoms than those that were not hospitalised during
the acute phase of illness. We consider hospitalisation
to be an indicator of the severity of the initial infection.
Our assumption that Q-fever patients with severe acute
illness are more likely to experience long-term impaired
QoL was therefore proven correct. Another study shows
that patients that had been admitted to the Intensive
Care Unit - regardless of the cause - have an impaired
QoL (SF-36) up to 18 months [29].
General QoL (44.9%) and fatigue (43.5%) were severely
affected in our study subjects. A small study on Dutch
Q-fever patients that measured the one year follow-up
and also used the NCSI reported a higher rate of 53% of
patients with severe fatigue [12]. We suspect that the
patients in that study had a higher hospitalisation rate
and presented with more pneumonia than our patients.
Consultation of our notification data confirmed this pre-
sumption, but the difference was marginal. Furthermore,
proportionally more patients in that study might have
been recruited from the local hospital’sc h e s tc l i n i c .I n
the present study, we approached all patients in the
region, regardless of the severity of the initial disease.
We found that heart disease increased the risk of sub-
jective symptoms, behavioural and subjective impair-
ment, HR QoL and dyspnoea emotions. Whereas lung
disease negatively influenced the outcomes of the first
three of these sub-domains.
Other authors stated that underlying heart [30,31] or
lung disease [32], arthritis [33], depression [34] and dia-
betes [35], all had a negative effect on the health status
in different sub-domains. We also found this effect,
except for diabetes, but could not compare data with
existing studies, as most of these studies focus on speci-
fic diseases (such as COPD) and grades of severity. We
however, combined all diseases of a certain tract.
Methodological considerations and study limitations
The NCSI is not widely used in Q-fever research. This
makes comparison to other QoL-research in Q-fever diffi-
cult. The advantage of the NCSI is that it provides a
detailed assessment including many domains of health sta-
tus covering symptoms, functional impairment and quality
of life. The NCSI provides more and specific information
on sub-domains than some of the other instruments such
as the SF-36. Furthermore, the availability of datasets of
both a COPD and a healthy norm group for the NCSI,
enabled us to compare the health status of Q-fever patients
with these two groups. Such a comparison provides useful
information for GPs and medical specialists in their under-
standing of Q-fever patients. Another advantage is that the
NCSI questionnaire for the domain fatigue is based on the
CIS (Checklist Individual Strength). This instrument cor-
rects for normal fatigue [36]. As many Q-fever patients suf-
fer from fatigue, the NCSI seemed the right choice.
Table 4 Probability of long-term impaired health-status amongst Q-fever patients older than 50 years (n = 277)
Domain Symptoms Functional impairment
Sub-domain Subjective symptoms N = 247 Dyspnoea emotions N =
166
Fatigue N = 201 Behavioural impairment N =
269
Factor N OR (95% CI ) P value N OR (95% CI ) P value N OR (95% CI ) P value N OR (95% CI) P value
Hospitalised 58 1.9 (1.1-3.6) 0.026 40 1.9 (0.9-3.8) 0.080 41 1.7 (0.8-3.4) 0.154 62 2.8 (1.5-5.1) 0.001
Diabetes 21 1.1 (0.4-2.6) 0.895 16 0.9 (0.3-2.7) 0.902 16 1.7 (0.6-4.9) 0.365 25 2.4 (0.9-5.9) 0.062
Heart disease 32 2.3 (1.1-5.2) 0.035 17 3.3 (1.1-9.3) 0.027 22 1.6 (0.6-4.2) 0.305 34 3.2 (1.4-7.3) 0.007
Lung disease 17 5.3 (1.5-18.7) 0.010 10 2.9 (0.8-10.3) 0.100 12 4.3 (0.9-19.8) 0.064 18 4.9 (1.4-17.5) 0.012
Arthritis 10 9.2 (1.2-73.9) 0.036 5 2.4 (0.4-14.9) 0.341 7 4.5 (0.5-38.4) 0.165 12 4.5 (0.9-21.0) 0.054
Depression 10 2.3 (0.6-9.2) 0.232 5 6.6 (0.7-60.6) 0.094 9 1.5 (0.4-6.1) 0.589 10 3.6 (0.7-17.1) 0.112
Domain Functional impairment Quality of Life (QoL)
Sub-domain Subjective impairment N =
241
General QoL N = 234 Health related QoL N = 263 Satisfaction relations N = 245
Factor N OR (95% CI) P value N OR (95% CI) P value N OR (95% CI) P value N OR (95% CI) P value
Hospitalised 52 1.4 (0.7-2.7) 0.274 47 0.9 (0.5-1.8) 0.894 47 2.3 (1.3-4.0) 0.005 56 1.3 (0.7-2.4) 0.343
Diabetes 23 1.3 (0.5-3.2) 0.570 18 0.6 (0.2-1.6) 0.298 18 1.2 (0.5-2.8) 0.626 24 0.8 (0.3-2.0) 0.649
Heart disease 30 2.7 (1.2-5.9) 0.011 25 1.4 (0.6-3.1) 0.469 25 2.6 (1.2-5.5) 0.014 33 1.8 (0.4-1.9) 0.692
Lung disease 16 13.3 (3.7-47.9) 0.000 13 0.9 (0.3-2.7) 0.869 13 2.1 (0.8-5.7) 0.128 15 2.1 (0.7-5.8) 0.159
Arthritis 11 12.1 (2.5-57.4) 0.002 7 1.6 (0.4-7.5) 0.522 7 7.0 (1.5-32.8) 0.013 11 1.1 (0.3-4.0) 0.827
Depression 9 1.9 (0.5-7.5) 0.329 8 9.0 (1.1-74.7) 0.041 8 3.1 (0.8-12.6) 0.100 10 8.7 (1.8-42.2) 0.007
Logistic regression modelling. In all determinants “no” was the reference. Smoking and education-level were not included due to overall insignificant results.
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fever patient reports of continuing respiratory com-
plaints. We therefore looked for a norm group with a
known respiratory component that we could compare
these Q-fever patients with. When we compared data
from Q-fever patients with the NCSI norm group of
COPD patients it should be realized that this is a speci-
fic subgroup of COPD patients with a severely impaired
health status in multiple sub-domains. We made the
choice to use this COPD norm group as we wished to
compare the long-term health status of Q-fever patients
(who often suffered a pneumonia initially) with another
group of patients with a known impaired health status.
The healthy control group was rather small with 65
individuals all over 50 years of age. However, the num-
ber of controls provided sufficient power for us to show
a large and clear difference between the groups.
Normative data of healthy subjects and those with
COPD were only available for patients over 50 years of
age. This was unfortunate as 46.2% of Q-fever patients
were younger than 50. As we chose our method to be as
strict and transparent as possible, we presented data for
patients over and under 50 separately.
In at least 1.6% of the Q-fever patients in the Dutch
2007-2008 cohorts, the condition became chronic (van
der Hoek et al, submitted for publication). For our study
population this could potentially mean eight or nine
patients with chronic Q-fever. As not all patients in our
study were followed up serologically we were unable to
establish if and who developed chronic Q-fever or any
of its presentations such as endocarditis.
Data were collected during the early stages of the Q-
fever outbreaks in the Netherlands. At that stage there
was little to no media attention for these outbreaks. The
general public was mostly unaware of Q-fever and the
possible negative long-term outcome. Patients were not
medicalised and mostly unaware. We therefore believe
that our data were not negatively influenced by the
media or the general knowledge of the patient of the
negative long-term outcomes.
Implications
By assessing the long-term health status of Q-fever
patients of the largest outbreak in the world, we are able
to describe and quantify the impact of Q-fever on patient’s
lives. Hospitalisation is an important predictor of severe
illness, poor long-term health status outcome and long-
term absence from work (unpublished data G.Morroy).
The outbreaks are continuing and Q-fever has become
endemic in the area. Since symptoms could last for ten
years or more [8], the burden of disease for the affected
communities is likely to be considerable.
A better understanding of long-term outcomes is
essential for policy makers dealing with these outbreaks.
GPs and other Medical Doctors should be aware that Q-
fever patients may present with long-term symptoms
especially in those that were hospitalised and or with co-
morbidity (heart-, lung-disease, and depression). Knowl-
edge of these detrimental long-term outcomes should
h e l pM D st ob em o r es u p p o r t i v et ot h e s ep a t i e n t sa n d
refer promptly and adequately to specialist care.
Conclusions
Our study of the largest described Q-fever cohort in the
world shows a large long-term impact of Q-fever on the
health status of Q-fever patients of all ages. This is but
an indication of the burden of disease in the years to
come considering the more than 4,000 reported Dutch
Q-fever cases since 2007. Policy makers ought to take
the long-term burden of disease into account, when
considering measures to be taken to curb these exten-
sive Dutch outbreaks. We recommend further research
to develop adequate prevention, treatment and revalida-
tion guidelines that might benefit these affected patients.
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